Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas

We conducted a phase I/II multicenter trial using six cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive B-cell lymphomas. Thirty-one patients were evaluable for toxicity and 29 for effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Svoboda, Jakub, Bair, Steven M., Landsburg, Daniel J., Nasta, Sunita Dwivedy, Nagle, Sarah J., Barta, Stefan K., Khan, Nadia, Filicko-O'Hara, Joanne, Gaballa, Sameh, Strelec, Lauren, Chong, Elise, Mitnick, Sheryl, Waite, Terease S., King, Cara, Ballard, Hatcher, Youngman, Matthew, Gerson, James, Plastaras, John P., Maity, Amit, Bogusz, Agata M., Hung, Stacy S., Nakamura, Hisae, Nejati, Reza, Steidl, Christian, Lim, Megan, Ruella, Marco, Schuster, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168499/
https://www.ncbi.nlm.nih.gov/pubmed/32414850
http://dx.doi.org/10.3324/haematol.2019.238675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168499/
https://www.ncbi.nlm.nih.gov/pubmed/32414850
http://dx.doi.org/10.3324/haematol.2019.238675

Ejemplares similares